

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

RD

RRID:CVCL_1649

Type: Cell Line

Proper Citation

RRID:CVCL_1649

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1649

Proper Citation: RRID:CVCL_1649

Description: Cell line RD is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Embryonal rhabdomyosarcoma

Defining Citation: [PMID:77569](#), [PMID:327080](#), [PMID:833871](#), [PMID:1917385](#), [PMID:2216456](#), [PMID:2302710](#), [PMID:3158613](#), [PMID:3518877](#), [PMID:4241949](#), [PMID:6220172](#), [PMID:6304521](#), [PMID:7309287](#), [PMID:8275086](#), [PMID:8383879](#), [PMID:10899454](#), [PMID:12068308](#), [PMID:16518851](#), [PMID:17471488](#), [PMID:18082704](#), [PMID:19235922](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20922763](#), [PMID:21948088](#), [PMID:22142829](#), [PMID:22460905](#), [PMID:22541669](#), [PMID:23578105](#), [PMID:23828214](#), [PMID:23882450](#), [PMID:25894527](#), [PMID:26351324](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31448612](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:36768928](#)

Comments: Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RD

Synonyms: R D, RD-2, RD 2, 130T, 130-T, 130 T, TE-32, TE 32, TE32, TE 32.T, Te 32.T

Cross References: BTO:BTO_0005377, CLO:CLO_0008693, CLO:CLO_0008770, EFO:EFO_0002315, CLDB:cl4119, CLDB:cl4120, CLDB:cl4121, CLDB:cl4122, CLDB:cl4123, CLDB:cl4124, CLDB:cl4125, CLDB:cl4126, CLDB:cl4127, AddexBio:C0035001/4950, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-136, ATCC:CRL-7713, ATCC:CRL-7731, ATCC:HTB-97, BCRC:60113, BCRJ:0260, BioGRID_ORCS_Cell_line:482, BioSample:SAMN01821591, BioSample:SAMN01821716, BioSample:SAMN03472710, BioSample:SAMN10988441, cancercellines:CVCL_1649, CCRID:1101HUM-PUMC000293, CCRID:1102HUM-NIFDC00079, CCRID:3101HUMTCHu45, CCRID:4201HUM-CCTCC00295, CCTCC:GDC0295, Cell_Model_Passport:SIDM00847, ChEMBL-Cells:ChEMBL3307547, ChEMBL-Targets:ChEMBL614144, CLS:300401, Cosmic:724833, Cosmic:801358, Cosmic:801760, Cosmic:802045, Cosmic:909264, Cosmic:1037298, Cosmic:1048111, Cosmic:1097753, Cosmic:1309330, Cosmic:1509195, Cosmic:1620036, Cosmic:1718099, Cosmic:2296987, Cosmic:2301590, Cosmic:2355912, Cosmic-CLP:909264, DepMap:ACH-000169, ECACC:85111502, EGA:EGAS00001000978, GDSC:909264, GEO:GSM185149, GEO:GSM186446, GEO:GSM219726, GEO:GSM887528, GEO:GSM888610, GEO:GSM1012752, GEO:GSM1670368, GEO:GSM1676309, GEO:GSM1701643, IARC_TP53:767, IGRhCellID:RD, IZSLER:BS TCL 57, JCRB:JCRB9072, KCLB:10136, LiGeA:CCLE_882, LINCS_LDP:LCL-1411, Lonza:1536, PharmacDB:RD_1296_2019, PRIDE:PXD000589, PRIDE:PXD007755, PRIDE:PXD030304, PRIDE:PXD039480, Progenetix:CVCL_1649, PubChem_Cell_line:CVCL_1649, TOKU-E:2986, Wikidata:Q54949532

ID: CVCL_1649

Record Creation Time: 20220427T221454+0000

Record Last Update: 20260905T182204+0000

Ratings and Alerts

No rating or validation information has been found for RD.

Warning: Discontinued: ATCC; HTB-97

Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: ATCC; CRL-7713

Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: ATCC; CRL-7731

Anecdotal: One of the 3 cell lines (HT-1080, RD and SK-N-SH) where the NRAS oncogene was first identified (PubMed=6304521)., Population: Caucasian., Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ying W, et al. (2026) Therapeutic targeting of YOD1 disrupts the PAX-FOXO1/N-Myc feedback loop in rhabdomyosarcoma. JCI insight, 11(3).

Burke CM, et al. (2026) Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. Molecular cancer therapeutics, 25(1), 156.

Koppenhafer SL, et al. (2026) DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. Oncogene, 45(28), 2823.

Kim H, et al. (2026) Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation. Cell.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Huang Y, et al. (2026) Mechanosensation promotes broad-spectrum antiviral defense through membrane remodeling. Cell chemical biology, 33(3), 307.

Li S, et al. (2026) Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies. Trends in biotechnology.

Kim A, et al. (2026) NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition. Molecular cancer therapeutics.

Wang S, et al. (2026) PhenoModel: A multimodal phenotypic drug design foundation model for discovering novel potential inhibitors of multiple cancer cells. Acta pharmaceutica Sinica. B, 16(3), 1219.

Liu X, et al. (2025) MFSD6 is an entry receptor for respiratory enterovirus D68. Cell host & microbe, 33(2), 267.

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. *Cancer immunology research*, 13(10), 1591.

Grizer CS, et al. (2025) Respiratory infection with Enterovirus D68 induces severe acute lung inflammation in the pediatric ferret model. *iScience*, 28(8), 113071.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. *iScience*, 28(8), 113149.

Mendes EA, et al. (2025) RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma. *bioRxiv : the preprint server for biology*.

Tiburcio PDB, et al. (2025) PD-L1 Expression is Mediated by microRNA Processing, Wnt/??-Catenin Signaling, and Chemotherapy in Wilms Tumor. *Pediatric blood & cancer*, 72(9), e31852.

Koppenhafer SL, et al. (2025) Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. *Cancer research communications*, 5(6), 1034.

Jolly JT, et al. (2025) Phosphatase activity is dispensable for PRL-3-mediated oncogenesis and tumor progression. *bioRxiv : the preprint server for biology*.

Su H, et al. (2025) Structure-Based Development of Ultra-Broad-Spectrum 3C-Like Protease Inhibitors. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e12342.

Larsen RK, et al. (2025) Non-cell-autonomous tumor promotion in DICER1 cancer predisposition. *Developmental cell*.

Ku D, et al. (2025) SLIRP amplifies antiviral signaling via positive feedback regulation and contributes to autoimmune diseases. *Cell reports*, 44(5), 115588.